Mineralys Therapeutics (NASDAQ:MLYS) CEO Sells $1,960,500.00 in Stock

Posted by Geri Gentry on Jul 3rd, 2026

Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) CEO Jon Congleton sold 75,000 shares of the business’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $26.14, for a total transaction of $1,960,500.00. Following the transaction, the chief executive officer owned 614,321 shares of the company’s stock, valued at $16,058,350.94. This trade represents a 10.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jon Congleton also recently made the following trade(s):

On Monday, April 13th, Jon Congleton sold 15,730 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $26.83, for a total transaction of $422,035.90.

Mineralys Therapeutics Stock Performance

NASDAQ MLYS opened at $27.69 on Friday. Mineralys Therapeutics, Inc. has a 52-week low of $12.59 and a 52-week high of $47.65. The company has a fifty day moving average of $27.10 and a 200-day moving average of $29.17. The company has a market capitalization of $2.28 billion, a P/E ratio of -13.51 and a beta of 0.66.

Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) last released its earnings results on Wednesday, May 6th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.04. As a group, analysts forecast that Mineralys Therapeutics, Inc. will post -2.3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on MLYS shares. HC Wainwright restated a “buy” rating on shares of Mineralys Therapeutics in a report on Monday, June 1st. Bank of America lifted their target price on shares of Mineralys Therapeutics from $46.00 to $51.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. TD Cowen initiated coverage on shares of Mineralys Therapeutics in a research note on Monday, April 27th. They issued a “buy” rating for the company. Jefferies Financial Group restated a “hold” rating on shares of Mineralys Therapeutics in a research report on Monday, June 1st. Finally, Wall Street Zen cut Mineralys Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Mineralys Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $49.33.

Check Out Our Latest Research Report on MLYS

Institutional Trading of Mineralys Therapeutics

Institutional investors have recently modified their holdings of the company. Navalign LLC bought a new stake in shares of Mineralys Therapeutics in the fourth quarter worth about $33,000. KBC Group NV bought a new position in Mineralys Therapeutics during the 1st quarter valued at approximately $33,000. Royal Bank of Canada lifted its holdings in Mineralys Therapeutics by 262.3% in the 4th quarter. Royal Bank of Canada now owns 1,529 shares of the company’s stock worth $56,000 after buying an additional 1,107 shares during the period. Caitong International Asset Management Co. Ltd lifted its holdings in Mineralys Therapeutics by 1,845.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,101 shares of the company’s stock worth $76,000 after buying an additional 1,993 shares during the period. Finally, Russell Investments Group Ltd. grew its position in shares of Mineralys Therapeutics by 14,091.3% in the 3rd quarter. Russell Investments Group Ltd. now owns 3,264 shares of the company’s stock worth $124,000 after buying an additional 3,241 shares during the last quarter. 84.46% of the stock is currently owned by hedge funds and other institutional investors.

About Mineralys Therapeutics

(Get Free Report)

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.